Lactobacillus acidophilus strain L.B (probiotic): benefits, dosage, contraindications
Scientific name(s)
Lactobacillus acidophilus
Family or group:
Probiotics
Indications
Rating methodology
EFSA approval.
Helicobacter pylori infection ✪✪✪✪✪
The antimicrobial effect of LB actives observed on enteropathogens has been demonstrated against Helicobacter pylori, a pathogenic germ involved in stomach disorders. In fact, in the presence of LB actives, the "urease" activity, which is an essential pathogenicity factor for Helicobacter's motility and its ability to colonize the mucosa, is significantly reduced.
Posologie
By oral route
A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates
Lactobacillus acidophilus LB: a useful pharmabiotic for the treatment of digestive disorders
Diarrhea ✪✪✪✪✪
LB actives have clinically demonstrated antisecretory activity. In fact, two randomized double-blind placebo-controlled clinical studies in children suffering from acute non-viral diarrhea showed a reduction of symptoms by around 40% in children who received LB actives compared to those who received a placebo.
Posologie
By oral route
Effectiveness and safety of Lactobacillus LB in the treatment of mild acute diarrhea in children
Clinical evaluation of the addition of lyophilized, heat-killed Lactobacillus acidophilus LB to oral rehydration therapy in the treatment of acute diarrhea in children
An experimental study and a randomized, double-blind, placebo-controlled clinical trial to evaluate the antisecretory activity of Lactobacillus acidophilus strain LB against nonrotavirus diarrhea
Bacterial infections ✪✪✪✪✪
LB actives exert an antibacterial effect against Salmonella typhi, by degradation of membrane polysaccharides and an increase in the permeability of the bacteria's outer membrane. The action of LB actives is equal or superior to that of the reference antibiotic (polymyxin) and cannot be attributed to lactic acid. Furthermore, LB actives exhibit antimicrobial activity against many other potentially pathogenic organisms: staphylococcus aureus, Listeria, Shigella, Escherichia coli, Klebsiella, Bacilus cereus, Pseudomonas aeruginosa, and Candida albicans.
Posologie
By oral route
Antagonistic activity against Helicobacter infection in vitro and in vivo by the human Lactobacillus acidophilus strain LB
A gastrointestinal anti-infectious biotherapeutic agent: the heat-treated Lactobacillus LB
Antibacterial effect of the adhering human Lactobacillus acidophilus strain LB.
A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates
Lactobacillus acidophilus LB: a useful pharmabiotic for the treatment of digestive disorders
Intestinal permeability ✪✪✪✪✪
Following an aggression by an infectious factor, stress, or repeated medication use, the cells of the intestinal mucosa can be altered. LB actives accelerate the repair of the cellular skeleton (protein actin network) and thus the functionality of the cell, contributing to reducing intestinal hyperpermeability. This action is observed in both the intestine and the stomach, to repair cellular lesions caused by Helicobacter pylori on the gastric mucosa.
Posologie
By oral route
Lactobacillus acidophilus LB: a useful pharmabiotic for the treatment of digestive disorders
Effectiveness and safety of Lactobacillus LB in the treatment of mild acute diarrhea in children
An experimental study and a randomized, double-blind, placebo-controlled clinical trial to evaluate the antisecretory activity of Lactobacillus acidophilus strain LB against nonrotavirus diarrhea
Candidiasis ✪✪✪✪✪
Vulvovaginal candidiasis are very common fungal infections that affect a large proportion of women of childbearing age. The pathogenic agent is usually Candida albicans, an opportunistic yeast that develops when the vaginal balance and the mechanism of local immunity are disrupted. Recolonizing the vagina with Lactobacillus acidophilus could restore vaginal pH and activate the normal growth of the bacterial flora. In the prevention of recurrences, the benefit of using probiotics is debated. In vitro studies have shown that lactobacilli can inhibit the growth of Candida albicans and/or its adhesion to the vaginal epithelium. Results from some clinical trials support the efficacy of certain strains of lactobacilli such as Lactobacillus acidophilus, Lactobacillus rhamnosus, and Lactobacillus fermentum, administered either orally or vaginally. A recent study reinforces these conclusions by showing that the addition of lactobacilli would enhance conventional fluconazole treatment.
Posologie
By oral route
Properties
Antimicrobial
The L.B strain has a strong inhibition capacity against the adhesion of enteropathogenic germs. In fact, they have antimicrobial activity against numerous potentially pathogenic organisms: staphylococcus aureus, Listeria, Salmonella, Shigella, Escherichia coli, Klebsiella, Bacilus cereus, Pseudomonas aeruginosa, and Candida albicans. The antimicrobial effect of LB actives observed on enteropathogens has also been demonstrated against Helicobacter pylori, a pathogenic germ involved in stomach disorders. In fact, in the presence of LB actives, the "urease" activity, which is an essential pathogenicity factor for Helicobacter's motility and its ability to colonize the mucosa, is significantly reduced.
Usages associés
Gastroprotective
LB actives exert a protective effect on enterocyte junctions, against alterations caused by certain medications. They reduce cell mortality and restore the natural tightness of the mucosa. Additionally, LB actives optimize the functionality of digestive mucous membranes thanks to antisecretory activity.
Usages associés
Digestive effect
Following an aggression by an infectious factor, stress, or repeated medication use, the cells of the intestinal mucosa can be altered. LB actives accelerate the repair of the cellular skeleton (protein actin network) and thus the functionality of the cell, contributing to reducing intestinal hyperpermeability. This action is observed in both the intestine and the stomach, to repair cellular lesions caused by Helicobacter pylori on the gastric mucosa.
Usages associés
Safety dosage
Child:
A review of 57 clinical trials showed that administering probiotics and/or symbiotic organisms to immunocompromised adults (HIV infection, patients with severe, surgical, or autoimmune disease) is safe. In particular, the safety of L. . acidophilus LB has been demonstrated in two controlled clinical trials and no adverse effects were reported.
Adult:
A review of 57 clinical trials showed that administering probiotics and/or symbiotic organisms to immunocompromised adults (HIV infection, patients with severe, surgical, or autoimmune disease) is safe. In particular, the safety of L. . acidophilus LB has been demonstrated in two controlled clinical trials and no adverse effects were reported.
